ESSA Pharma Inc. (EPIX): Price and Financial Metrics


ESSA Pharma Inc. (EPIX): $3.60

-0.15 (-4.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EPIX Stock Price Chart Interactive Chart >

Price chart for EPIX

EPIX Price/Volume Stats

Current price $3.60 52-week high $14.88
Prev. close $3.75 52-week low $1.40
Day low $3.53 Volume 163,800
Day high $3.78 Avg. volume 1,127,532
50-day MA $2.75 Dividend yield N/A
200-day MA $4.31 Market Cap 158.66M

ESSA Pharma Inc. (EPIX) Company Bio


ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.


EPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

EPIX Latest Social Stream


Loading social stream, please wait...

View Full EPIX Social Stream

Latest EPIX News From Around the Web

Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.

EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Positive Preliminary Results from Combination Therapy of EPI-7386 and Enzalutamide On October 28, 2022, ESSA Pharma Inc (NASDAQ:EPIX) announced multiple poster presentations at the 29th Annual Prostate Cancer Foundation Scientific Retreat, including an update on the Phase 1/2 Study of EPI-7386 in combination with

Yahoo | November 14, 2022

ESSA Pharma to Participate in Two Upcoming Investor Conferences

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.

Yahoo | November 10, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Good morning, investor!

William White on InvestorPlace | November 7, 2022

Bloom Burton Keeps Their Buy Rating on ESSA Pharma (EPIX)

Bloom Burton analyst Prasath Pandurangan maintained a Buy rating on ESSA Pharma (EPIX - Research Report) on October 31 and set a price target of $23.00. The company's shares opened today at $3.49.According to TipRanks, Pandurangan is ranked #7578 out of 7929 analysts.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ESSA Pharma with a $23.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $14.88 and a one-year low of $1.40. Currently, ESSA Pharma has an average volume of 3.17M.

Catie Powers on TipRanks | November 2, 2022

Examining Penny Stocks with Technical Analysis for November 2022

Technical analysis (TA) involves the careful study of a stock's chart patterns and trends. Although this set of skills may seem daunting at first, even beginners can incorporate a few select TA methodologies into their investing strategy to great success.

Yahoo | November 2, 2022

Read More 'EPIX' Stories Here

EPIX Price Returns

1-mo 7.46%
3-mo N/A
6-mo -29.55%
1-year -69.13%
3-year -27.93%
5-year -26.23%
YTD -74.65%
2021 19.03%
2020 116.91%
2019 161.90%
2018 -52.05%
2017 -90.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6146 seconds.